Background
Methods
Patient selection
Tissue microarray construction
Immunohistochemistry
Scoring
Statistical analysis
Results
Patients’ clinical characteristics
Immunohistochemical analysis
Normal Endometrium | Ovarian Endometriosis | Peritoneal Endometriosis | Deep-Infiltrating Endometriosis | |
---|---|---|---|---|
Epithelium
| ||||
GPER cyt | 1.2 (±1.7, 0–4) | 6.5 (±3.5, 0–12) | 5.0 (±3.7, 0–10) | 4.0 (±2.8, 0–8) |
GPER nuc | 6.4 (±2.6, 0–12) | 6.9 (±1.8, 3–8) | 8.5 (±3.8, 2–12) | 5.4 (±2.2, 2–12) |
ER alpha | 10.6 (±2.4, 3–12) | 8.6 (±3.5, 2–12) | 11.4 (±1.6, 6–12) | 9.8 (±2.7, 3–12) |
ER beta | 2.4 (±2.2, 0–8) | 5.4 (±2.6, 0–10) | 7.4 (±1.5, 4–10) | 4.5 (±2.5, 0–8) |
PR | 11.5 (±1.7, 3–12) | 4.6 (±4.3, 0–12) | 10.9 (±2.4, 3–12) | 9.2 (±3.7, 2–12) |
Stroma
| ||||
GPER nuc | 7.7 (±3.0, 2–12) | 10.7 (±1.6, 8–12) | 11.7 (±0.8, 9–12) | 10.1 (±1.9, 6–12) |
ER alpha | 8.7 (±3.1, 2–12) | 10.6 (±2.1, 6–12) | 11.3 (±1.6, 6–12) | 10.1 (±3.0, 2–12) |
ER beta | 1.8 (±2.0, 0–8) | 5.4 (±2.3, 0–10) | 7.6 (±1.3, 4–10) | 3.9 (±2.3, 0–8) |
PR | 11.7 (±0.9, 8–12) | 11 (±1.4, 8–12) | 10.4 (±2.5, 3–12) | 11 (±2.1, 4–12) |
Frequencies of low and high expression groups
Receptor | Expression level | Endometrium | Endometriosis | p-value |
---|---|---|---|---|
GPER cyt | High | 0/30 | 30/60 (50%) | <0.001 |
Low | 30/30 (100%) | 30/60 (50%) | ||
GPER nuc | High | 19/30 (63.3%) | 42/60 (70%) | 0.6 |
Low | 11/30 (36.7%) | 18/60 (30%) | ||
ER-alpha | High | 28/30 (93.3%) | 57/63 (90.5%) | 0.7 |
Low | 2/30 (6.7%) | 6/63 (9.5%) | ||
ER-beta | High | 3/30 (10%) | 35/65 (53.8%) | <0.001 |
Low | 27/30 (90%) | 30/65 (46.2%) | ||
PR | High | 29/30 (96.7%) | 42/60 (70%) |
0.005
|
Low | 1/30 (3.3%) | 18/60 (30%) |
Receptor | Expression level | Endometrium | Endometriosis | p-value |
---|---|---|---|---|
GPER nuc | High | 23/30 (76.7%) | 74/74 (100%) | <0.001 |
Low | 7/30 (23.3%) | 0/74 | ||
ER-alpha | High | 25/30 (83.3%) | 68/70 (97.1%) |
0.02
|
Low | 5/30 (16.7%) | 2/70 (2.9%) | ||
ER-beta | High | 2/30 (6.7%) | 35/71 (49.3%) | <0.001 |
Low | 28/30 (93.3%) | 36/71 (50.7%) | ||
PR | High | 30/30 (100%) | 70/72 (97.2%) | 0.6 |
Low | 0/30 | 2/72 (2.8%) |
Receptor | Expression level | Ovarian Endometriosis | Peritoneal Endometriosis | Deep infiltrating Endometriosis | p-value |
---|---|---|---|---|---|
GPER cyt | High | 14/20 (70.0%) | 9/18 (50.0%) | 7/22 (31.8%) |
0.01
|
Low | 6/20 (30.0%) | 9/18 (50.0%) | 15/22 (68.2%) | ||
GPER nuc | High | 16/20 (80.0%) | 13/18 (72.2%) | 13/22 (59.1%) | 0.2 |
Low | 4/20 (20.0%) | 5/18 (27.8%) | 9/22 (40.9%) | ||
ER-alpha | High | 18/23 (78.3%) | 17/17 (100%) | 22/23 (95.7%) |
0.02
|
Low | 5/23 (21.7%) | 0/17 | 1/23 (4.3%) | ||
ER-beta | High | 11/24 (45.8%) | 15/17 (88.2%) | 9/24 (37.5%) |
0.001
|
Low | 13/24 (54.2%) | 2/17 (11.8%) | 15/24 (62.5%) | ||
PR | High | 8/21 (38.1%) | 16/17 (94.1%) | 18/22 (81.8%) | <0.001 |
Low | 13/21 (61.9%) | 1/17 (5.9%) | 4/22 (18.2%) |
Receptor | Expression level | Ovarian Endometriosis | Peritoneal Endometriosis | Deep infiltrating Endometriosis | p-value |
---|---|---|---|---|---|
GPER nuc | High | 27/27 (100%) | 19/19 (100%) | 28/28 (100%) | - |
Low | 0/27 | 0/19 | 0/28 | ||
ER-alpha | High | 25/25 (100%) | 18/18 (100%) | 25/27 (92.6%) | 0.2 |
Low | 0/25 | 0/18 | 2/27 (7.4%) | ||
ER-beta | High | 11/27 (40.7%) | 17/18 (94.4%) | 7/26 (26.9%) | <0.001 |
Low | 16/27 (59.3%) | 1/18 (5.6%) | 19/26 (73.1%) | ||
PR | High | 26/26 (100%) | 18/19 (94.7%) | 26/27 (96.3%) | 0.3 |
Low | 0/26 | 1/19 (5.3%) | 1/27 (3.7%) |